Moderna Inc. Stock

Shares of vaccine maker Moderna (NASDAQ: MRNA) have been rallying this year, and at one point, they were up more than double where they started the year. Growth investors appear to be encouraged by

Explore the exciting world of Moderna (NASDAQ: MRNA) with our contributing expert analysts in this Motley Fool Scoreboard episode. Check out the video below to gain valuable insights into market

Moderna's (NASDAQ: MRNA) shares have already soared by 92% this year. Yet, the biotech is racing toward another catalyst. The company could receive an important regulatory approval on Aug. 5. Should

Moderna (NASDAQ: MRNA) soared onto the scene in early pandemic days with its messenger RNA technology and delivered a coronavirus vaccine in a matter of months. As the vaccine brought in blockbuster

Moderna's (NASDAQ: MRNA) share price has more than doubled this year as the market has grown increasingly optimistic about the company's pipeline and encouraging regulatory progress for its flu

Moderna (NASDAQ: MRNA) stock jumped about 10% on Thursday to $79.76 -- a fresh high for the year and the latest leg of a run that has carried shares up more than 70% in a month.

The catalyst? In

As the biotechnology landscape shifts toward personalized medicine and advanced computing, investors are weighing established leaders against emerging tech-driven disruptors. Moderna (NASDAQ:MRNA)

After a significant slump following the height of the COVID-19 pandemic, Moderna (NASDAQ: MRNA) share prices have ripped higher over the past year, surging nearly 150%. Various factors have driven

Moderna (NASDAQ: MRNA) has been on fire this year. As of this writing, the company's shares have slightly more than doubled to date. What's more, the biotech has an important catalyst on the

Moderna (NASDAQ: MRNA) stock skyrocketed in early pandemic days -- and the company became a household name -- as it launched its coronavirus vaccine. This first product, and one using the new

Shares of Moderna (NASDAQ: MRNA) jumped during the COVID-19 pandemic, but when its COVID-19 vaccine revenue dried up, the stock slumped. However, the company has recently shown it isn't a one-trick

Despite economic headwinds and geopolitical tensions, equities have performed fairly well so far this year. The S&P 500 is up by a solid 8% to date. Some companies are doing an even more impressive

Moderna (NASDAQ: MRNA) is best known for its COVID-19 vaccines, which were fast-tracked for approval in 2020 and subsequently generated tens of billions of dollars in revenue.

However, a lot has

Eli Lilly (NYSE: LLY), Merck (NYSE: MRK), and Pfizer (NYSE: PFE) are among the largest pharmaceutical companies in the world. The first focuses primarily on developing medicines for diabetes and

Some investors might choose to stay out of the famously volatile biotech industry right now, given that equities are already facing plenty of uncertainty that has rocked the market. However, even in

While the stock market is facing significant volatility right now, there is a decent chance it will still perform fairly well over the next five years. That's what we have come to expect from

Moderna (NASDAQ: MRNA) is best known for its coronavirus vaccine, a product that generated more than $18 billion in revenue at its peak in 2022 and helped drive the stock higher during the early

Moderna (NASDAQ: MRNA) soared into the spotlight during the pandemic thanks to its mRNA technology and its rapid development of a coronavirus vaccine. But it's those two elements that have weighed

Moderna (NASDAQ: MRNA) became a household name during the coronavirus pandemic. There's a good reason for that: Its mRNA technology enabled the rapid development of a vaccine. The financial benefit

Vaccine specialist Moderna (NASDAQ: MRNA) stock soared 5.5% through 12:55 p.m. ET Wednesday after The Wall Street Journal reported that the U.S. Food and Drug Administration will accept (note